DDI-DrugBank.d666.s0 >> Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents. >> 37-45,92-111
DDI-DrugBank.d666.s1 >> Patients receiving pindolol plus a catecholamine-depleting agent should, therefore, be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope, or postural hypotension. >> 19-26
DDI-DrugBank.d666.s2 >> Pindolol has been used with a variety of antihypertensive agents, including hydrochlorothiazide, hydralazine, and guanethidine without unexpected adverse interactions. >> 0-7,41-63,76-94,97-107,114-125
DDI-DrugBank.d666.s3 >> Pindolol has been shown to increase serum thioridazine levels when both drugs are co-administered. >> 0-7,42-53
DDI-DrugBank.d666.s4 >> Pindolol levels may also be increased with this combination. >> 0-7
DDI-DrugBank.d666.s5 >> Risk of anaphylactic reaction: While taking beta blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic. >> 44-56
DDI-DrugBank.d666.s6 >> Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reactions. >> 56-66
